Evolent Announces Third Quarter 2026 Results

Evolent posts strong revenue growth but faces margin pressure and ongoing net losses.

What the company is saying

Evolent Health, Inc. (NYSE:EVH) highlights a 51% year-over-year revenue increase to $725,367,000 for Q3 2026, positioning itself as a growth leader in specialty healthcare solutions. CEO Seth Blackley frames the narrative around robust demand, citing renewals and expansions with major health plan customers and successful 2026 oncology launches as key drivers. The company emphasizes its innovative AI platform and oncology offerings as future growth and margin catalysts, projecting confidence in continued expansion. Evolent renews its largest Surgical Management contract for four years and secures two new revenue agreements, including a major oncology services expansion set to go live January 1, 2027, covering about 1 million Commercial lives. The tone is optimistic, with management reiterating full-year revenue guidance of $2.6–$2.7 billion and raising Adjusted EBITDA guidance to $130–$135 million, while acknowledging that reconciliation to GAAP net income is not feasible due to non-core adjustments. The announcement foregrounds topline growth and contract wins, but addresses margin compression and ongoing losses less directly.

What the data suggests

The disclosed figures show revenue rising from $479,533,000 in Q3 2025 to $725,367,000 in Q3 2026, a 51% increase. Net loss attributable to common shareholders narrows to $23,566,000 from $26,930,000, improving the net loss margin from (5.6)% to (3.2)%. Adjusted EBITDA falls to $34,257,000 from $38,955,000, with margin dropping to 4.7% from 8.1%, indicating profitability challenges despite higher revenue. Adjusted income attributable to common shareholders improves to $7,296,000 ($0.06 per share) from $5,630,000 ($0.05 per share). Cash and cash equivalents stand at $148,255,000 as of September 30, 2026. The Medical Expense Ratio increases to 93.0% from 85.0%, reflecting higher costs relative to revenue. The company reiterates full-year revenue guidance of $2.6–$2.7 billion and raises Adjusted EBITDA guidance to $130–$135 million, signaling confidence in near-term performance. Evolent expects $26–$28 million in capitalized expenditures for 2026. The operational data is comprehensive, but the impact of new contracts—such as the 'approximately 1 million Commercial lives'—is not fully substantiated with contract documentation. The evidence supports strong top-line momentum but reveals margin compression and continued net losses.

Analysis

The announcement presents a balanced tone, with most claims supported by realised financial and operational data, such as revenue, net loss, and adjusted EBITDA for Q3 2026. There is some narrative inflation in the forward-looking statements about future growth and margin expansion, as well as in the guidance for 2026, but these are typical for quarterly results and are not excessive. The company discloses both top-line and profitability metrics, but margin compression and a continued net loss temper the positive narrative. The renewal and expansion of contracts are concrete, though the impact of the 'approximately 1 million Commercial lives' is not fully substantiated with contract documentation. The capital outlay for 2026 is moderate and not paired with long-dated, uncertain returns. Overall, the gap between narrative and evidence is modest, with most claims grounded in disclosed results, but some forward-looking optimism is present.

Risk flags

• ●Margin compression is evident, with Adjusted EBITDA margin falling from 8.1% to 4.7% year-over-year, despite strong revenue growth. This suggests rising costs are outpacing revenue gains, which could limit future profitability if not addressed.
• ●The company continues to report net losses, with a Q3 2026 net loss attributable to common shareholders of $23,566,000. Persistent losses raise questions about the path to sustainable profitability, especially as medical expense ratios rise.
• ●Evolent's forward-looking guidance for Adjusted EBITDA and revenue is not reconcilable to GAAP net income due to unspecified non-core adjustments. This lack of transparency in bridging non-GAAP and GAAP results makes it harder for investors to assess true underlying profitability.
• ●The operational impact of new contracts, such as the expansion to approximately 1 million Commercial lives, is not fully substantiated with detailed contract documentation or breakdowns. This introduces uncertainty about the scale and timing of future revenue contributions.
• ●Capitalized expenditures of $26–$28 million are planned for 2026, which, while moderate, add to execution risk if these investments do not translate into improved margins or profitability within the expected timeframe.

Bottom line

Evolent Health delivers strong revenue growth and narrows its net loss, but margin compression and ongoing losses temper the positive narrative. The company is winning and renewing significant contracts, including a major oncology expansion set to launch imminently, supporting its raised full-year guidance. However, the drop in Adjusted EBITDA margin and the inability to reconcile non-GAAP guidance to GAAP profitability highlight ongoing cost and transparency challenges. Investors should focus on whether Evolent can translate topline momentum into sustainable margin improvement and eventual net profitability. The most important takeaway is that while growth is robust and guidance is optimistic, the company must demonstrate cost discipline and clearer profitability pathways to fully realize its potential.

Announcement summary

(NYSE:EVH) Evolent Health, Inc. announced financial results for the three months ended September 30, 2026. Revenue for the quarter was $725,367,000, compared to $479,533,000 for the same period in 2025. Net loss attributable to common shareholders was $23,566,000, versus $26,930,000 in the prior year quarter. Net loss margin was (3.2)% compared to (5.6)% in Q3 2025. Adjusted EBITDA was $34,257,000, down from $38,955,000, with an Adjusted EBITDA margin of 4.7% versus 8.1% last year. Average Lives on Platform/Cases for the Performance Suite were 7,195, up from 6,474, while Specialty Technology and Services Suite averaged 74,733, down from 78,050. Administrative Services averaged 1,163, compared to 1,222, and Cases were 11, down from 13. Average Unique Members were 39,804, compared to 40,781. Average PMPM Fees/Revenue per Case for the Performance Suite was $26.14, up from $14.77, while Specialty Technology and Services Suite was $0.32, down from $0.40. Administrative Services PMPM was $13.84, down from $15.77. Medical Expense Ratio was 93.0%, up from 85.0%. Evolent announced one renewal and two new revenue agreements in the quarter, bringing the year-to-date total to seven. The company renewed its largest Surgical Management customer contract for four years. Evolent expanded an existing client relationship to provide oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live, and added Member Navigation across all existing and new lives. Evolent also expanded its relationship with a national payer in Specialty Technology & Services for oncology across 11 additional states. Cost of revenue for the quarter was $636,946,000, and selling, general and administrative expenses were $73,116,000. Loss per share attributable to common shareholders was $(0.21), compared to $(0.24) in Q3 2025. Total cash and cash equivalents as of September 30, 2026, was $148,255,000. Adjusted cost of revenue was $635,107,000, and adjusted selling, general and administrative expenses were $56,003,000. Adjusted income attributable to common shareholders was $7,296,000, or $0.06 per share, compared to $5,630,000, or $0.05 per share, in Q3 2025. For the nine months ended September 30, 2026, revenue was $1,874,133,000, and for the same period in 2025, it was $1,407,510,000. For the full year 2026, Evolent reiterated its revenue guidance range of $2.6 billion to $2.7 billion and raised its Adjusted EBITDA guidance to $130.0 million to $135.0 million. The company expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026. Goodwill as of September 30, 2026, was $694,420,000, and intangible assets, net, were $539,172,000. Total assets as of September 30, 2026, were $1,962,156,000.

Disagree with this article?